Reported Sunday, Lilly Brings Updated Phase 3 Selpercatinib Data Versus Cabozantinib Or Vandetanib In RET-Mutant Medullary Thyroid Cancer To ESMO 2026, Alongside Sofetabart Mipitecan, Olomorasib And Abemaciclib Presentations

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation

Updated first-line data for olomorasib, an investigational therapy targeting KRAS G12C-mutant NSCLC, to be featured in a rapid oral presentation

Updated Phase 3 data for selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant MTC to be shared in a proffered paper